BOULDER, CO–Peak Pharmaceuticals, Inc. (OTCQB: CTCO), formerly Cannabis Therapy Corp. (the “Company”), a growth stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, hemp-based medicinal therapies and supplements (Nutraceuticals), wishes to advise that on December 23, 2014, Cannabis Therapy Corp., a Nevada corporation, entered into an Agreement and Plan of Merger pursuant to which the shareholders of the Company became shareholders of the surviving company named Peak Pharmaceuticals, Inc., a Nevada corporation.
The Company’s common stock will temporarily remain listed for quotation on OTC Markets under the current symbol “CTCO” until a new symbol is assigned by Financial Industry Regulatory Authority, Inc. (FINRA). The Company will publicly announce the new trading symbol when assigned by FINRA and the effective date of the symbol change.
Peak Pharmaceuticals President and CEO Dr. Soren Mogelsvang states, “The name change was made to make our name more consistent with our business operations and plans relating to development, manufacturing and marketing of hemp-based, pharmaceutical-grade, nutraceutical and supplement products for the human and animal health markets.”
Additional details of the Company’s business, finances, appointments and agreements can be found as part of the Company’s continuous public disclosure as a reporting issuer with the Securities and Exchange Commission (“SEC”) available at www.sec.gov. For more information please visit www.peakpharma.com.
About Peak Pharmaceuticals, Inc. (OTCQB: CTCO)
Peak Pharmaceuticals, Inc. specializes in the development, manufacturing, sales and marketing of pharmaceutical-grade, hemp-based nutraceutical and supplement products for the human and animal health markets. The company aims to become a global leader in the research, development, sales and marketing of medicinal hemp and cannabinoid products. For more information visit www.peakpharma.com